A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation.
Germany, Belgium, Netherlands, Denmark, Spain, Greece, Poland, Hungary, France, Italy, Bulgaria, Romania
Condition studied
Chronic Obstructive Pulmonary Disease
Investigational medicinal product(s)
Novolizer Salbutamol 100 microgrammes/dosepoudre pour inhalationSterile 0.9% (w/v) sodium chloride solution in single-use PFS
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
Annualized rate of moderate/severe exacerbations.
Endpoint detail
Time to first moderate/severe exacerbation., Change from baseline in SGRQ total score (measured using the SGRQ-C) at Week 52., Change from baseline in E-RS: COPD total score at Week 52.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.